OCUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ocular Therapeutix Inc (OCUL) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The strong analyst ratings, significant hedge fund buying, and promising drug pipeline outweigh the recent financial challenges and insider selling. While the technical indicators are neutral, the long-term potential of the company in addressing unmet medical needs in a $14B market justifies the investment.
The MACD histogram is positive at 0.147, indicating bullish momentum, though it is contracting. RSI is at 63.08, which is neutral. Moving averages are converging, suggesting no clear trend. Key support is at 8.67, and resistance is at 9.709. The stock is trading near resistance levels in pre-market at $9.51.
Analysts have raised price targets significantly, with targets ranging from $27 to $34, citing strong Phase 3 trial results and the potential approval of Axpaxli.
Hedge funds are heavily buying, with a 2312.47% increase in buying activity last quarter.
The company's drug pipeline addresses a $14B market with unmet needs in wet AMD.
Insiders are selling, with a 186.05% increase in selling activity over the last month.
Financial performance shows a YoY revenue decline of 22.43%, though net income has improved.
The market reacted negatively to the SOL-1 trial results due to the Eylea arm outperforming expectations.
In Q4 2025, revenue dropped by 22.43% YoY to $13.25M. Net income improved by 33.62% YoY to -$64.65M. EPS remained flat at -0.29. Gross margin decreased by 5.20% YoY to 87.97%. While revenue and gross margin declined, the improvement in net income indicates better cost management.
Analysts are overwhelmingly positive, with multiple firms reiterating Buy ratings and raising price targets. BofA and Clear Street highlighted the strong Phase 3 trial results and the potential for Axpaxli to address unmet needs in a $14B market. Jefferies and Citizens view the recent stock selloff as an attractive entry point, with price targets ranging from $27 to $34.
